Evidence map›Paper›PMID 24330498›Full record

ArticleBMC cancer2013

Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.

Meriem Hasmim, Cécile Badoual, Philippe Vielh, Françoise Drusch, Virginie Marty, Agnès Laplanche, Mariana de Oliveira Diniz, Hélène Roussel, Eléonore De Guillebon, Stéphane Oudard and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Development of head and neck pathology in Europe.Virchows Archiv : an international journal of pathology · 2022
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Differential expression ofEXCLI journal · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Meriem Hasmim
Cécile Badoual
Philippe Vielh
Françoise Drusch
Virginie Marty
Agnès Laplanche
Mariana de Oliveira Diniz
Hélène Roussel
Eléonore De Guillebon
Stéphane Oudard
Stéphane Hans
Eric Tartour
Salem ChouaibU753-INSERM, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, France. chouaib@igr.fr.
Institut Gustave Roussy · FRInserm · FRUniversité Paris Cité · FRDélégation Paris 5 · FRHôpital Européen Georges-Pompidou · FRSorbonne Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOur group has previously shown that EPHRIN-A1 and SCINDERIN expression by tumor cells rendered them resistant to cytotoxic T lymphocyte-mediated lysis. Whereas the prognostic value of EPHRIN-A1 expression in cancer has already been studied, the role of SCINDERIN presence remains to be established. In the present work, we investigated the prognosis value of EPHRIN-A1 and SCINDERIN expression in head and neck carcinomas. In addition, we monitored the HLA-class I expression by tumor cells and the presence of tumor-infiltrating CD8+ T cells to evaluate a putative correlation between these factors and the survival prognosis by themselves or related to EPHRIN-A1 and SCINDERIN expression.

methodsTumor tissue sections of 83 patients with head and neck cancer were assessed by immunohistochemistry for the expression of EPHRIN-A1, SCINDERIN, HLA class I molecules and the presence of CD8+ T cells.

resultsNo significant prognosis value could be attributed to these factors independently, despite a tendency of association between EPHRIN-A1 and a worse clinical outcome. No prognostic value could be observed when CD8+ T cell tumor infiltration was analyzed combined with EPHRIN-A1, SCINDERIN or HLA class I expression.

conclusionThese results highlight that molecules involved in cancer cell resistance to cytotoxic T lymphocytes by themselves are not a sufficient criteria for prognosis determination in cancer patients. Other intrinsic or tumor microenvironmental features should be considered in prognostic evaluation.

Indexed as

AgedBiomarkers, TumorCarcinoma, Squamous CellCD8-Positive T-LymphocytesCombined Modality TherapyCytotoxicity, ImmunologicEphrin-A1FemaleGelsolinHead and Neck NeoplasmsHistocompatibility Antigens Class IHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisBiomarkers, TumorEphrin-A1GelsolinHistocompatibility Antigens Class Iscinderin

Identifiers

PMID24330498
PMCPMC3867221
OpenAlexW2062528848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.